Editorial

Getting a CLEARER Picture: Bempedoic Acid and Cardiovascular Outcomes in Patients with Statin Intolerance

Authors: Laura A. Campbell, MD, Jessica P. Ammon, DO, Christopher D. Jackson, MD

Abstract

Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality in the United States and worldwide.1 In 2019, the prevalence of ASCVD in the United States was 24 million people, affecting approximately 10% of the population older than 21 years.2 An established link exists between lower levels of low-density lipoprotein-cholesterol (LDL-C) and reduced morbidity and mortality from CVD.2

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. J Am Coll Cardiol 2019; 74:1376–1414.
 
2. Gu J, Sanchez RJ, Chauhan A, et al. Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: a 2019 update. Am J Prev Cardiol 2022;10:100336.
 
3. Gaine SP, Kulkarni A, Dixon DL, et al. NLA 2022 definition of statin intolerance. https://www.acc.org/latest-in-cardiology/articles/2022/08/08/12/27/nla-2022-definition-of-statin-intolerance. Published August 17, 2022. Accessed September 21, 2023.
 
4. Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol 2022;16: 361–375.
 
5. Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J 2022;43:3213–3223.
 
6. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and management. Eur Heart J 2015;36:1012–1022.
 
7. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. J Am Coll Cardiol 2022;80:1366–1418.
 
8. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023;388:1353–1364.
 
9. Ballantyne CM, Bays H, Catapano AL, et al. Role of bempedoic acid in clinical practice. Cardiovasc Drugs Ther 2021;35:853–864.
 
10. Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019;380: 1022–1032.